UBS Starts Diplomat Pharmacy (DPLO) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- Lula, Brazil's iconic working class president, wins historic fourth term in dramatic comeback
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
- Accenture shares fall on insider sales and analyst downgrade
- Wall Street closes lower to end rocky week
- Credo Technology shares fall on competition concerns
Mizuho Securities Cuts Price Target as Recent Sell-offs of Specialty Pharma Manufactures Negatively Effect Diplomat Pharmacy (DPLO)
October 21, 2015 6:43 AM EDTMizuho Securities maintained a Buy rating on Diplomat Pharmacy (NYSE: DPLO), and cut the price target to $44.00 (from $53.00), following recent sell-offs of specialty pharmacy manufactures. DPLO does not distribute any VRX or HZNP products. DPLO manages and distributes complex drugs for chronic conditions unlike... More



